Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets ready-to-use injectable and infusible drug formulations. The company is headquartered in Chicago, Illinois.
| Revenue (TTM) | $335.41M |
| Gross Profit (TTM) | $290.38M |
| EBITDA | $48.77M |
| Operating Margin | 5.62% |
| Return on Equity | -617.00% |
| Return on Assets | 6.13% |
| Revenue/Share (TTM) | $1.99 |
| Book Value | $-0.06 |
| Price-to-Book | 107.68 |
| Price-to-Sales (TTM) | 4.95 |
| EV/Revenue | 5.21 |
| EV/EBITDA | 73.14 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 28.70% |
| Shares Outstanding | $182.32M |
| Float | $176.00M |
| % Insiders | 3.06% |
| % Institutions | 60.12% |
Volatility is currently contracting
Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for a dedicated Program Overview webinar for XP-8121, the Company's Phase 3-ready, once-weekly subcutaneous levothyroxine injection in development for the treatment of hypothyroidism. The XP-8121 webinar will take place on Wednesday, Septemb.
Xeris Biopharma Holdings, Inc. achieved record 2024 revenues of $203M, up 24%, with robust growth across all three commercial products. 2025 revenue guidance of $255M–$275M implies 30% growth for XERS at midpoint, supporting a forward P/S ratio of ~3.4x and fair valuation. XP-8121, a once-weekly injectable levothyroxine, targets a $1B+ U.S. market and could be a future blockbuster pending Phase 3 trial initiation.
Xeris Biopharma NASDAQ: XERS reported second-quarter total revenue of $92.1 million, up 29% from a year earlier, as net product revenue increased 34% to $91 million. The company raised the low end of its full-year 2026 revenue outlook, now forecasting total revenue of $385 million to $390 million.
Xeris Biopharma Holdings, Inc. (XERS) Q2 2026 Earnings Call Transcript
The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced its financial results for the second quarter ended June 30, 2026. "The second quarter was another strong period for Xeris, with net product revenue growing 34% year-over-year, driven by Recorlev's exceptional commercial momentum,” said John Shannon,.
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2026 financial results before the open of the U.S. financial markets on Thursday, August 6, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the C.
Xeris Biopharma (XERS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Please replace the release issued earlier today with the following corrected version that provides additional information regarding the inducement grants. The corrected release reads: XERIS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today anno.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on XERS and any ticker you trade — then tracks every position and per-strategy win rate.
